However, the royalty narrative carries concentration risk. Some market commentary suggests the "royalty waterfall" may reverse as certain partnerships expire and licenses are lost, potentially causing revenue streams to decline. The company also faces ongoing litigation in the Delaware Court of Chancery, where a post-trial briefing schedule was approved on July 28, 2026, with oral argument set for October 20, 2026. The outcome could affect royalty obligations, including a Sagard Healthcare Royalty Partners agreement dating to October 2021 that is expected to be settled by mid-2027.
Technically, ANAB shares recently crossed above their 50-day moving average of $58.02, trading as high as $58.54 on August 15 with volume of 330,882 shares. The stock carries a market capitalization of $1.73 billion and a beta of 0.72. Analyst sentiment remains mixed: nine buy ratings, two holds, and one sell, with a consensus price target of $82.00.
What to Watch
The upcoming earnings release will test whether Jemperli's growth trajectory can offset the structural headwinds of a maturing royalty portfolio and whether the market rewards the simplified, high-margin royalty model. Investors will watch for royalty revenue guidance, updates on the Sagard obligation timeline, and any commentary on the pending litigation.
Can a single-asset royalty stream with a defined expiration profile sustain a premium valuation once the growth phase transitions to harvest mode?
Sources: Source 1 · Source 2 · Source 3 · Source 4 · Source 5 · Source 6
